MENU
MAZE
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Maze Therapeutics (MAZE) Ownership - Who owns Maze Therapeutics?
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity... Show more
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
530.82M
P/E Ratio
170.52
Total Cash
294.37M
Projected Growth
N/A
Total Debt
25.82M
Revenue
167.5M
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash/Share
6.72
Total Debt/Equity
N/A
Revenue/Share
3.82 USD as % of share price
Fundamentals
MAZE
Capitalization
531M
P/E Ratio
170.52
Risk (Beta)
N/A
Dividend Yield
N/A
Total Cash
294M
Total Cash/Share
6.72
Total Debt
25.8M
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
3.82%
Revenue
168M
ROE
N/A
Book Value
292M
P/B Ratio
1.82
Cash Flow
N/A
Earnings
0.07
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
44K
Current Ratio
16.10
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
53.2M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
0.94
Shares Held By Institutions
384M
Shares Outstanding - Current
43.8M
Total Liabilities
40.8M
Total Volume MTD
N/A
Value
-1
Gain YTD
N/A
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information